TSKI-VI

structure given in first source

Also Known As:

N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine; TSKI VI; TSKIVI; 2,2'-((2-methyl-1,4-piperazinediyl)bis(methylene(2-oxo-1H-indol-1-yl-3(2H)-ylidene)))bis(hydrazinecarbothioamide)

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiosemicarbazones: 649
    - Methisazone: 49
      - TSKI-VI: 1
- Semicarbazides: 7
  - Semicarbazones: 67
    - Thiosemicarbazones: 649
      - Methisazone: 49
        TSKI-VI: 1
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Methisazone: 49
        TSKI-VI: 1

Related Diseases

1.	Vaccinia 12/01/1980 - "N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. "
2.	Pseudorabies 12/01/1980 - "N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. "
3.	Encephalitis (Encephalitis, Rasmussen) 12/01/1980 - "N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. "
4.	Body Weight (Weight, Body) 12/01/1980 - "N,N'-bis(methylisatin-beta-thiosemicarbazone)-2-methylpiperazine (TSKI-VI) proved to be significantly effective against lethal vaccinia, pseudorabies and Mengo virus-induced encephalitis in different strains of mice when administered subcutaneously (s.c.) in doses of 20 mg/kg body weight, twice daily, for a period of five days. "

Related Drugs and Biologics

1.	TSKI-VI